How to find the best strategy for you ?
Value
Our factor investing score meticulously assesses the intrinsic value of each asset, providing invaluable insights into its potential for long-term growth.
Growth
With a keen focus on growth prospects, our factor investing score analyzes each asset's trajectory, offering strategic guidance for maximizing returns in dynamic market conditions..
Quality
With an emphasis on quality metrics, our factor investing score meticulously evaluates the fundamental strength and stability of each asset, safeguarding your portfolio against potential risks.
Volatility
By meticulously evaluating volatility, our factor investing score helps you navigate market turbulence, ensuring a balanced portfolio resilient to unpredictable fluctuations.
Momentum
Leveraging momentum analysis, our factor investing score identifies assets poised for upward trends, empowering you to capitalize on market momentum for optimized performance.
Yield
Focused on yield optimization, our factor investing score identifies assets with attractive income potential, enabling you to construct a diversified portfolio tailored to your income objectives.
Create a reliable strategy with the A-Score
Undervalued company with stable and reliable business like Warren Buffet
Get detailled Investment Case for more than 5500 Stocks
Strong Company Updates
Get a complete corporate access : reliable, clear, and always available at the time you need it
Doximity(DOCS): Doximity Delivers Solid Q4 Results, Eyes AI‑Driven Growth
Q4 revenue rose to $145 million, a 5% year‑over‑year increase, while free cash flow hit a record $107 million. Full‑year revenue reached $645 million, up 13% YoY, with an adjusted EBITDA margin of 55%. EPS came in at $0.26 versus analyst estimates of $0.28<sup>1</sup>. The stock trades at a P/E of 16.98 and an EV/EBITDA of 12.92, indicating modest valuation upside relative to peers.
May -14
Enovix(ENVX): Enovix Q1 2026: Battery Breakthroughs Fuel Strong Growth
Revenue surged to $7.6 million, a 49 % YoY jump, topping the high end of guidance and supported by a 26.3 % non‑GAAP gross margin, the sixth straight positive quarter. The company posted a non‑GAAP loss from operations of $28.8 million, better than the $29‑$32 million range forecast, and an EPS of –$0.14 versus the –$0.15 estimate. Cash and equivalents stood at $582.7 million. Staff highlighted the robust pipeline as a key growth engine. Valuation metrics show a modest EV/EBITDA of 1.52 and a P/S ratio of 0.18, indicating a low‑priced profile relative to peers.
May -14
Genmab(GMAB.CO): Genmab Q1 2026: Strong Growth, Pipeline Momentum
Genmab delivered a robust Q1 2026, posting $1.1 billion in revenue—up 25% YoY—boosted by $200 million in royalties from DARZALEX and Kesimpta and $137 million in EPKINLY sales. Operating profit rose 23% to $260 million, and EPS hit $5.38 versus consensus $10.1. The firm’s P/E of 6.16 and EV/EBITDA of 3.94 underscore a valuation anchored in disciplined cost control and high ROIC of 43.78%.
May -14
Quality Equity Research. Easy Access
Get started with our cost-effective equity research
Monthly
Annual Up to 30% Discount
Free Trial
FREE
7 Days- Unlimited access to Watchlist
- Unlimited access to screener
- Unlimited access to AI Assistant
- Access to US Investment Case
- API calls limited to 10/day
- Request new coverage
- Premium Support
Premium
$39.99
per month
- Unlimited access to Watchlist
- Unlimited access to screener
- Unlimited access to AI Assistant
- Unlimited access to Investment Case
- API calls limited to 250/day
- Request new coverage
- Premium Support
Ultimate
$99.90
- Unlimited access to Watchlist
- Unlimited access to screener
- Unlimited access to AI Assistant
- Unlimited access to Investment Case
- API calls limited to 2500/minute
- Request new coverage
- Premium Support
